The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 Mar 2018 10:05

RNS Number : 1153H
N4 Pharma PLC
08 March 2018
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

N4 PHARMA PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

X

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

NIGEL JAMES THEOBALD

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

8 MARCH 2018

8 MARCH 2018

7. Threshold(s) that is/are crossed orreached: vi, vii

19%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00BYW8QM32

16,846,633

16,846,633

16,846,633

16,846,633

18.91%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

16,846,633

18.91%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

The Company's issued share capital increased on 8 March 2018 as a result of exercises of warrants

14. Contact name:

Nigel Theobald

15. Contact telephone number:

+ 44 1332 690061

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFIIVVITIIT
Date   Source Headline
24th Sep 20187:00 amRNSAcceptance of Nuvec® on EUNCL
20th Sep 20187:01 amRNSInterim Results
20th Sep 20187:00 amRNSStrategic Review
30th Jul 201811:05 amRNSSecond Price Monitoring Extn
30th Jul 201811:00 amRNSPrice Monitoring Extension
30th Jul 20187:00 amRNSChange of Adviser
17th Jul 20181:12 pmRNSHolding(s) in Company
11th Jul 20182:05 pmRNSSecond Price Monitoring Extn
11th Jul 20182:00 pmRNSPrice Monitoring Extension
9th Jul 20187:00 amRNSClinical trials preliminary results
18th Jun 20187:00 amRNSNuvec® Update
23rd May 201811:31 amRNSResult of AGM
9th May 20187:00 amRNSFiling of Patent
27th Apr 201811:00 amRNSPosting of Annual Report and Notice of AGM
25th Apr 20187:00 amRNSFinal Results
18th Apr 20187:00 amRNSCommencement of Sildenafil Clinical Trial
9th Apr 201811:00 amRNSPrice Monitoring Extension
9th Mar 20188:43 amRNSExercise of Warrants and Total Voting Rights
8th Mar 201810:05 amRNSHolding(s) in Company
8th Mar 20187:00 amRNSNuvec® Update
7th Mar 20188:33 amRNSExercise of Warrants and Total Voting Rights
2nd Mar 201812:17 pmRNSChange of Adviser
26th Feb 20189:27 amRNSExercise of Warrants and Total Voting Rights
21st Feb 20181:36 pmRNSExercise of Warrants and Total Voting Rights
19th Feb 20185:01 pmRNSExercise of Warrants and Total Voting Rights
14th Feb 20185:26 pmRNSExercise of Warrants and Total Voting Rights
13th Feb 201812:52 pmRNSExercise of Warrants and Total Voting Rights
12th Feb 20182:05 pmRNSSecond Price Monitoring Extn
12th Feb 20182:00 pmRNSPrice Monitoring Extension
12th Feb 201811:06 amRNSSecond Price Monitoring Extn
12th Feb 201811:00 amRNSPrice Monitoring Extension
8th Feb 201812:01 pmRNSHolding(s) in Company
8th Feb 201811:46 amRNSExercise of Warrants and Total Voting Rights
5th Feb 20187:00 amRNSIssue of Equity and Director/PDMR Shareholding
2nd Feb 20184:47 pmRNSExercise of Warrants and Total Voting Rights
2nd Feb 20181:04 pmRNSAward of Grant and Collaboration with MedImmune UK
30th Jan 20183:04 pmRNSExercise of Warrants and Total Voting Rights
24th Jan 20184:06 pmRNSExercise of Warrants and Total Voting Rights
24th Jan 20181:19 pmRNSGlobal Business Accelerator Programme in Japan
22nd Jan 201810:44 amRNSExercise of Warrants and Total Voting Rights
15th Jan 201812:36 pmRNSHolding(s) in Company
8th Jan 20182:31 pmRNSExercise of Warrants and Total Voting Rights
8th Jan 20181:26 pmRNSHolding(s) in Company
28th Dec 20179:03 amRNSExercise of Warrants and Total Voting Rights
22nd Dec 20177:00 amRNSFiling of Patent
18th Dec 20178:27 amRNSHolding(s) in Company
13th Dec 20174:07 pmRNSExercise of Warrants and Total Voting Rights
29th Nov 201711:12 amRNSViagra switch to OTC status in the UK
10th Nov 20174:04 pmRNSDirector/PDMR Shareholding
8th Nov 20177:00 amRNSResults of latest nuvec pre-clinical study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.